Dendrimer Scaffolds for Pharmaceutical Use
    6.
    发明申请
    Dendrimer Scaffolds for Pharmaceutical Use 有权
    树枝状支架用于制药用途

    公开(公告)号:US20150225439A1

    公开(公告)日:2015-08-13

    申请号:US14425602

    申请日:2013-09-05

    摘要: This invention relates to certain dendrimer compounds. In particular, this invention relates to novel dendrimer compounds that can be elaborated to give increasingly large and complex compounds. These elaborated compounds can be attached to, or can encapsulate within, active agent(s) so as to beneficially modify the characteristics of that active agent. Alternatively, the elaborated compounds can themselves be beneficially modified into therapeutic agents by the attachment of inactive agents.

    摘要翻译: 本发明涉及某些树枝状大分子化合物。 特别地,本发明涉及新颖的树枝状大分子化合物,其可以被精心制备以产生越来越大的和复杂的化合物。 这些精制化合物可以附着于活性剂或可以包封在活性剂中,以有利地改变该活性剂的特性。 或者,精制的化合物本身可以通过无活性剂的附着而有益地修饰成治疗剂。

    Method Of Controlling Crystallization
    8.
    发明申请
    Method Of Controlling Crystallization 审中-公开
    控制结晶的方法

    公开(公告)号:US20120193574A1

    公开(公告)日:2012-08-02

    申请号:US13393523

    申请日:2010-08-26

    摘要: The invention provides a method of crystallising a compound comprising either: (i) providing a first confined solution comprising the compound; and adding more of the compound to and/or increasing the degree of saturation of the first confined solution, whereby to provide a resultant second confined solution that comprises more compound and/or that has a greater degree of supersaturation relative to a confined supersaturated solution of the same compound stabilised solely by being confined; or (ii) providing a first confined melt comprising the compound; and cooling and/or increasing the pressure of the first confined melt, whereby to provide a resultant second confined melt that is cooler and/or is more pressurised relative to a confined super-cooled melt of the same compound stabilised solely by being confined, whereby to effect the crystallising under confinement and under thermodynamic control.

    摘要翻译: 本发明提供一种结晶化合物的方法,包括:(i)提供包含该化合物的第一限制溶液; 并且将更多的化合物加入到和/或增加第一限制溶液的饱和度,从而提供所得到的第二约束溶液,其包含更多的化合物和/或相对于约束过饱和溶液的过饱和溶液具有更大程度的过饱和度 相同的化合物仅通过限制而稳定; 或(ii)提供包含所述化合物的第一限制熔体; 并且冷却和/或增加第一限制熔体的压力,由此提供相对于仅通过限制稳定稳定的相同化合物的约束过冷却熔体而更冷和/或加压的所得第二约束熔体,由此 在限制和热力学控制下实现结晶。

    Process for producing optically active beta-hydroxy-alpha-aminocarboxylic acid ester
    9.
    发明授权
    Process for producing optically active beta-hydroxy-alpha-aminocarboxylic acid ester 失效
    光学活性β-羟基-α-氨基羧酸酯的制备方法

    公开(公告)号:US08207370B2

    公开(公告)日:2012-06-26

    申请号:US12311325

    申请日:2007-09-26

    摘要: It is an objective of the present invention to produce an anti-form of an optically active β-hydroxy-α-aminocarboxylic acid ester efficiently, simply and industrially advantageously. The objective can be accomplished by directly and selectively producing the anti-form of the optically active β-hydroxy-α-aminocarboxylic acid ester by asymmetric reduction of a β-keto-α-aminocarboxylic acid ester using an optically active amine complex as a catalyst. Further, the β-keto-α-aminocarboxylic acid ester as a raw material can be produced at a high yield by reacting a glycine derivative with a carboxylic acid derivative.

    摘要翻译: 本发明的目的是在工业上有效地有效地制备光学活性的α-羟基-α-氨基羧酸酯的抗反型剂。 该目的可以通过使用光学活性胺络合物不对称还原反应形式的光学活性的β-羟基-α-氨基羧酸酯来直接和选择性地制备 催化剂 此外,可以通过使甘氨酸衍生物与羧酸衍生物反应,以高产率制备作为原料的α-酮-α-氨基羧酸酯。